Top

International Journal of Clinical Oncology

Published in:

21-04-2022 | Mesothelioma | Original Article

What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey

Authors: Selma Metintas, Guntulu Ak, Emine Dundar, Muzaffer Metintas

Published in: International Journal of Clinical Oncology | Issue 7/2022

Abstract

Objectives

To investigate the changes in epidemiological and survival characteristics of malignant mesothelioma (MM) cases diagnosed in a 30-year period between 1990 and 2019.

Methods

Data were analyzed considering three time periods (1990–1999, 2000–2009, 2010–2019) when treatment practices changed. The Join point Regression Program was used to analyze the change in clinical and epidemiological characteristics of the cases. Kaplan–Meier analysis was used to calculate the overall survival of the patients. Cox regression analysis was used to determine the effect of variables on survival.

Results

The study group consisted of 928 MM patients. During the study period, the mean age of the patients and the percentage of epithelioid subtype increased, while the percentage of female and histopathologically unidentified cases decreased. The median survival (95%CI) of patients according to the study periods was 9.0 (7.2–10.9), 9.0 (7.6–10.4) and 12.0 (10.5–13.5) months, respectively. A significant increase in overall survival was observed in the time trend (p = 0.013). There was no significant change in overall survival in patients receiving best supportive care over the 30-year period (p = 0.060), but an improvement of 1.4 (95%CI 0.2 to 2.7) months (p = 0.027) was observed in patient receiving chemotherapy. An improvement in overall survival of 4.8 (1.2 to 8.4) months was also observed in patients receiving multimodality treatment during 2000–2019 (p = 0.014). MM patients who were younger, female, diagnosed after 2000, epithelioid subtype, early stage, and received chemotherapy or multimodal treatment had longer survival.

Conclusions

It was found that histopathological diagnosis and treatment success in MM have improved over the years.

Sirri E, Kieschke J, Vohmann C et al (2020) GEKID cancer survival working group, survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: a population-based study. Int J Cancer 147(6):1548–1558. https://doi.org/10.1002/ijc.32931CrossRefPubMed

Metintaş S, Batırel HF, Bayram H et al (2017) Turkey national mesothelioma surveillance and environmental asbestos exposure control program. Int J Environ Res Public Health 14(11):1293. https://doi.org/10.3390/ijerph14111293CrossRefPubMedCentral

Plato N, Martinsen JI, Sparén P et al (2016) Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos ban. Epidemiol Health 38:e2016039. https://doi.org/10.4178/epih.e2016039CrossRefPubMedPubMedCentral

Delgermaa V, Takahashi K, Park EK et al (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89(10):716–724. https://doi.org/10.2471/BLT.11.086678CrossRefPubMedPubMedCentral

Metintas S, Metintas M, Ucgun I et al (2002) Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 122(6):2224–2229. https://doi.org/10.1378/chest.122.6.2224CrossRefPubMed

Metintas S, Ak G, Metintas M (2019) A review of the cohorts with environmental and occupational mineral fiber exposure. Arch Environ Occup Health 74(1–2):76–84. https://doi.org/10.1080/19338244.2018.1467873CrossRefPubMed

Galateau-Salle F, Churg A, Roggli V et al (2016) World Health Organization Committee for tumors of the pleura, the 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol 11(2):142–154. https://doi.org/10.1016/j.jtho.2015.11.005CrossRefPubMed

Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644. https://doi.org/10.1200/JCO.2003.11.136CrossRefPubMed

Krug LM, Pass HI, Rusch VW et al (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27(18):3007–3013. https://doi.org/10.1200/JCO.2008.20.3943CrossRefPubMedPubMedCentral

10.

Treasure T, Lang-Lazdunski L, Waller D et al (2011) MARS trialists, extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12(8):763–772. https://doi.org/10.1016/S1470-2045(11)70149-8CrossRefPubMedPubMedCentral

11.

LeStang N, Bouvier V, Glehen O et al (2019) Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: a population-based study. Cancer Epidemiol 60:106–111. https://doi.org/10.1016/j.canep.2019.03.014CrossRef

12.

Baas P, Daumont MJ, Lacoin L et al (2021) Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: a nationwide CAS registry analysis from the I-O optimise initiative. Lung Cancer 162:185–193. https://doi.org/10.1016/j.lungcan.2021.11.001CrossRefPubMed

13.

Brambilla E, Travis WD, Colby TV et al (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18(6):1059–1068. https://doi.org/10.1183/09031936.01.00275301CrossRefPubMed

14.

Travis WD, Brambilla E, Burke AP et al (2015) Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10(2015):1240–1242. https://doi.org/10.1097/JTO.0000000000000663CrossRefPubMed

15.

Husain AN, Colby TV, Ordóñez NG et al (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 142(1):89–108. https://doi.org/10.5858/arpa.2017-0124-RACrossRefPubMed

16.

Nicholson AG, Sauter JL, Nowak AK et al (2020) EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 15(1):29–49. https://doi.org/10.1016/j.jtho.2019.08.2506CrossRefPubMed

17.

Galateau-Salle F, Churg A, Roggli V et al (2016) World Health Organization committee for tumors of the pleura, the 2015 World Health Organization classification of tumors of the pleura, advances since the 2004 classification. J Thorac Oncol 11(2):142–154. https://doi.org/10.1016/j.jtho.2015.11.005CrossRefPubMed

18.

Metintas M, Ozdemir N, Hillerdal G et al (1999) Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med 93(5):349–355. https://doi.org/10.1016/s0954-6111(99)90318-9CrossRefPubMed

19.

https://data.tuik.gov.tr/Kategori/GetKategori?p=Nufus-ve-Demografi-109. Accessed 26 Aug 2021

20.

Metintas M, Ak G, Dundar E et al (2010) Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest 137(6):1362–1368. https://doi.org/10.1378/chest.09-0884CrossRefPubMed

21.

Beebe-Dimmer JL, Fryzek JP, Yee CL et al (2016) Mesothelioma in the United States: a surveillance, epidemiology, and end results (seer)-medicare investigation of treatment patterns and overall survival. Clin Epidemiol 8:743–750. https://doi.org/10.2147/CLEP.S105396CrossRefPubMedPubMedCentral

22.

Metintas S, Ak G, Bogar F et al (2017) Asbestos knowledge and awareness level in central part of Anatolia. Int J Occup Environ Health 23(3):243–249. https://doi.org/10.1080/10773525.2018.1470789CrossRefPubMed

23.

Sugarbaker DJ, Richards WG, Bueno R (2014) Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 260(4):577–580. https://doi.org/10.1097/SLA.0000000000000903CrossRefPubMed

24.

Cao CQ, Yan TD, Bannon PG et al (2010) A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 5(10):1692–1703. https://doi.org/10.1097/JTO.0b013e3181ed0489CrossRefPubMed

25.

Rusch VW, Chansky K, Kindler HL et al (2016) IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions, the IASLC mesothelioma staging project: proposals for the m descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol 11(12):2112–2119. https://doi.org/10.1016/j.jtho.2016.09.124CrossRefPubMed

26.

Ak G, Metintas S, Akarsu M et al (2015) The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma. BMC Cancer 15:510. https://doi.org/10.1186/s12885-015-1519-zCrossRefPubMedPubMedCentral

27.

Friedberg JS, Culligan MJ, Tsao AS et al (2019) A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint national cancer institute-international association for the study of lung cancer-mesothelioma applied research foundation taskforce. J Thorac Oncol 14(8):1343–1353. https://doi.org/10.1016/j.jtho.2019.04.029CrossRefPubMed

28.

Woolhouse I, Bishop L, Darlison L et al (2018) British thoracic society guideline for the investigation and management of malignant pleural mesothelioma. Thorax 73(Suppl 1):i1–i30. https://doi.org/10.1136/thoraxjnl-2017-211321CrossRefPubMed

29.

Taioli E, Wolf AS, Camacho-Rivera M et al (2015) Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients. PLoS ONE 10(12):e0145039. https://doi.org/10.1371/journal.pone.0145039CrossRefPubMedPubMedCentral

Title: What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey
Authors: Selma Metintas
Guntulu Ak
Emine Dundar
Muzaffer Metintas
Publication date: 21-04-2022
Publisher: Springer Nature Singapore
Keywords: Mesothelioma
Cytostatic Therapy
Published in: International Journal of Clinical Oncology / Issue 7/2022
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-022-02168-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2022

Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer

Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis

Establishment and validation of a nomogram for predicting potential lateral pelvic lymph node metastasis in low rectal cancer

Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinoma

Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801

Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer